REG - IXICO plc - Issue of share options and PDMR dealing

IXICOAnnouncement

07/02/2025 15:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250207:nRSG3983Wa&default-theme=true

RNS Number : 3983W  IXICO plc  07 February 2025

IXICO PLC

("IXICO" or the "Company")

Issue of share options

 

7 February 2025 - London, UK. IXICO plc (AIM: IXI, "IXICO" or "the Company") a
global leader in neuroscience imaging, using its AI-driven platform to help
advance therapy research in neurological disorders, confirms that share option
awards covering 7,413,488 shares, which were proposed by, and discussed with,
the Company's major shareholders in October 2024 (see: Circular
(https://ixico.com/assets/Investors-Finance/Circular-and-Notice-of-GM.pdf) )
and approved pursuant to a resolution supported by 99.76% of the shareholder
vote at the Annual General Meeting of 24 January 2025 have been issued today.

 

Full details of the terms of the options were set out in the Notice of AGM
(see: AGM resolutions
(https://ixico.com/assets/Investors-Finance/IXICO-AGM-2025-Notice-of-Meeting.pdf)
)

 

Ends

 

 

Further information:

 

 IXICO plc                                                                         +44 (0) 20 3763 7499
 Bram Goorden, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and                          +44 (0) 20 7220 0500

 Sole Broker)
 Giles Balleny / Dan Hodkinson (Corporate Finance)

 Nigel Birks (Life Science Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson / Tamar Cranford Smith (Sales)

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Bram Goorden

 2    Reason for the notification

 a)   Position/status                                              Chief Executive Officer

 b)   Initial notification /Amendment                              Initial

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         IXICO plc

 b)   LEI                                                          2138005M1F59O6HWSA97

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Options over ordinary shares in IXICO plc

      Identification code                                          ISIN: GB00BFXR4C20

 b)   Nature of the transaction                                    Grant of Share Options

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     1 pence           4,448,093

 d)   Aggregated information

                                                                   N/A - single transaction
      - Aggregated volume

      - Price

 e)   Date of the transaction                                      7  February 2025

 f)   Place of the transaction                                     Off Market Transaction

 

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Grant Nash

 2    Reason for the notification

 a)   Position/status                                              Chief Financial Officer

 b)   Initial notification /Amendment                              Initial

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         IXICO plc

 b)   LEI                                                          2138005M1F59O6HWSA97

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Options over ordinary shares in IXICO plc

      Identification code                                          ISIN: GB00BFXR4C20

 b)   Nature of the transaction                                    Grant of Share Options

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     1 pence           2,965,395

 d)   Aggregated information

                                                                   N/A - single transaction
      - Aggregated volume

      - Price

 e)   Date of the transaction                                      7 February 2025

 f)   Place of the transaction                                     Off Market Transaction

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUPUAAPUPAGCM